
Global Favipiravir Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
Description
Global Favipiravir Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
Summary
According to APO Research, The global Favipiravir market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Favipiravir is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Favipiravir is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Favipiravir is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Favipiravir is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Favipiravir include ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma, Cipla, Lupin, Sun Pharma and Hisun Pharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Favipiravir, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Favipiravir, also provides the sales of main regions and countries. Of the upcoming market potential for Favipiravir, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Favipiravir sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Favipiravir market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Favipiravir sales, projected growth trends, production technology, application and end-user industry.
Favipiravir segment by Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Favipiravir segment by Type
Brand Drug
Generic Drug
Favipiravir segment by Application
Influenza Viruses
COVID-19
Others
Favipiravir segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Favipiravir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Favipiravir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Favipiravir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Favipiravir market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Favipiravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Favipiravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
181 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Favipiravir Market Size, 2019 VS 2023 VS 2030
- 1.3 Global Favipiravir Market Size Estimates and Forecasts (2019-2030)
- 1.4 Global Favipiravir Sales Estimates and Forecasts (2019-2030)
- 1.5 Global Favipiravir Market Average Price (2019-2030)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Favipiravir Market Dynamics
- 2.1 Favipiravir Industry Trends
- 2.2 Favipiravir Industry Drivers
- 2.3 Favipiravir Industry Opportunities and Challenges
- 2.4 Favipiravir Industry Restraints
- 3 Favipiravir Market by Manufacturers
- 3.1 Global Favipiravir Revenue by Manufacturers (2019-2024)
- 3.2 Global Favipiravir Sales by Manufacturers (2019-2024)
- 3.3 Global Favipiravir Average Sales Price by Manufacturers (2019-2024)
- 3.4 Global Favipiravir Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
- 3.5 Global Favipiravir Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Favipiravir Manufacturers, Product Type & Application
- 3.7 Global Favipiravir Manufacturers Commercialization Time
- 3.8 Market Competitive Analysis
- 3.8.1 Global Favipiravir Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Favipiravir Players Market Share by Revenue in 2023
- 3.8.3 2023 Favipiravir Tier 1, Tier 2, and Tier 3
- 4 Favipiravir Market by Type
- 4.1 Favipiravir Type Introduction
- 4.1.1 Brand Drug
- 4.1.2 Generic Drug
- 4.2 Global Favipiravir Sales by Type
- 4.2.1 Global Favipiravir Sales by Type (2019 VS 2023 VS 2030)
- 4.2.2 Global Favipiravir Sales by Type (2019-2030)
- 4.2.3 Global Favipiravir Sales Market Share by Type (2019-2030)
- 4.3 Global Favipiravir Revenue by Type
- 4.3.1 Global Favipiravir Revenue by Type (2019 VS 2023 VS 2030)
- 4.3.2 Global Favipiravir Revenue by Type (2019-2030)
- 4.3.3 Global Favipiravir Revenue Market Share by Type (2019-2030)
- 5 Favipiravir Market by Application
- 5.1 Favipiravir Application Introduction
- 5.1.1 Influenza Viruses
- 5.1.2 COVID-19
- 5.1.3 Others
- 5.2 Global Favipiravir Sales by Application
- 5.2.1 Global Favipiravir Sales by Application (2019 VS 2023 VS 2030)
- 5.2.2 Global Favipiravir Sales by Application (2019-2030)
- 5.2.3 Global Favipiravir Sales Market Share by Application (2019-2030)
- 5.3 Global Favipiravir Revenue by Application
- 5.3.1 Global Favipiravir Revenue by Application (2019 VS 2023 VS 2030)
- 5.3.2 Global Favipiravir Revenue by Application (2019-2030)
- 5.3.3 Global Favipiravir Revenue Market Share by Application (2019-2030)
- 6 Global Favipiravir Sales by Region
- 6.1 Global Favipiravir Sales by Region: 2019 VS 2023 VS 2030
- 6.2 Global Favipiravir Sales by Region (2019-2030)
- 6.2.1 Global Favipiravir Sales by Region (2019-2024)
- 6.2.2 Global Favipiravir Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Favipiravir Sales Growth Rate by Country: 2019 VS 2023 VS 2030
- 6.3.2 North America Favipiravir Sales by Country (2019-2030)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.4 Europe
- 6.4.1 Europe Favipiravir Sales Growth Rate by Country: 2019 VS 2023 VS 2030
- 6.4.2 Europe Favipiravir Sales by Country (2019-2030)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Favipiravir Sales Growth Rate by Country: 2019 VS 2023 VS 2030
- 6.5.2 Asia Pacific Favipiravir Sales by Country (2019-2030)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 LAMEA
- 6.6.1 LAMEA Favipiravir Sales Growth Rate by Country: 2019 VS 2023 VS 2030
- 6.6.2 LAMEA Favipiravir Sales by Country (2019-2030)
- 6.6.3 Mexico
- 6.6.4 Brazil
- 6.6.5 Turkey
- 6.6.6 GCC Countries
- 7 Global Favipiravir Revenue by Region
- 7.1 Global Favipiravir Revenue by Region
- 7.1.1 Global Favipiravir Revenue by Region: 2019 VS 2023 VS 2030
- 7.1.2 Global Favipiravir Revenue by Region (2019-2024)
- 7.1.3 Global Favipiravir Revenue by Region (2025-2030)
- 7.1.4 Global Favipiravir Revenue Market Share by Region (2019-2030)
- 7.2 North America
- 7.2.1 North America Favipiravir Revenue (2019-2030)
- 7.2.2 North America Favipiravir Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.3 Europe
- 7.3.1 Europe Favipiravir Revenue (2019-2030)
- 7.3.2 Europe Favipiravir Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Favipiravir Revenue (2019-2030)
- 7.4.2 Asia-Pacific Favipiravir Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.5 LAMEA
- 7.5.1 LAMEA Favipiravir Revenue (2019-2030)
- 7.5.2 LAMEA Favipiravir Revenue Share by Country: 2019 VS 2023 VS 2030
- 8 Company Profiles
- 8.1 ChemRar Group
- 8.1.1 ChemRar Group Comapny Information
- 8.1.2 ChemRar Group Business Overview
- 8.1.3 ChemRar Group Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.1.4 ChemRar Group Favipiravir Product Portfolio
- 8.1.5 ChemRar Group Recent Developments
- 8.2 Glenmark
- 8.2.1 Glenmark Comapny Information
- 8.2.2 Glenmark Business Overview
- 8.2.3 Glenmark Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.2.4 Glenmark Favipiravir Product Portfolio
- 8.2.5 Glenmark Recent Developments
- 8.3 Fujifilm
- 8.3.1 Fujifilm Comapny Information
- 8.3.2 Fujifilm Business Overview
- 8.3.3 Fujifilm Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.3.4 Fujifilm Favipiravir Product Portfolio
- 8.3.5 Fujifilm Recent Developments
- 8.4 Dr. Reddy
- 8.4.1 Dr. Reddy Comapny Information
- 8.4.2 Dr. Reddy Business Overview
- 8.4.3 Dr. Reddy Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.4.4 Dr. Reddy Favipiravir Product Portfolio
- 8.4.5 Dr. Reddy Recent Developments
- 8.5 R-Pharma
- 8.5.1 R-Pharma Comapny Information
- 8.5.2 R-Pharma Business Overview
- 8.5.3 R-Pharma Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.5.4 R-Pharma Favipiravir Product Portfolio
- 8.5.5 R-Pharma Recent Developments
- 8.6 Cipla
- 8.6.1 Cipla Comapny Information
- 8.6.2 Cipla Business Overview
- 8.6.3 Cipla Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.6.4 Cipla Favipiravir Product Portfolio
- 8.6.5 Cipla Recent Developments
- 8.7 Lupin
- 8.7.1 Lupin Comapny Information
- 8.7.2 Lupin Business Overview
- 8.7.3 Lupin Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.7.4 Lupin Favipiravir Product Portfolio
- 8.7.5 Lupin Recent Developments
- 8.8 Sun Pharma
- 8.8.1 Sun Pharma Comapny Information
- 8.8.2 Sun Pharma Business Overview
- 8.8.3 Sun Pharma Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.8.4 Sun Pharma Favipiravir Product Portfolio
- 8.8.5 Sun Pharma Recent Developments
- 8.9 Hisun Pharm
- 8.9.1 Hisun Pharm Comapny Information
- 8.9.2 Hisun Pharm Business Overview
- 8.9.3 Hisun Pharm Favipiravir Sales, Price, Revenue and Gross Margin (2019-2024)
- 8.9.4 Hisun Pharm Favipiravir Product Portfolio
- 8.9.5 Hisun Pharm Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Favipiravir Value Chain Analysis
- 9.1.1 Favipiravir Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Favipiravir Production Mode & Process
- 9.2 Favipiravir Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Favipiravir Distributors
- 9.2.3 Favipiravir Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.